Tempus AI, Inc. Class A ( (TEM) ) has released its Q3 earnings. Here is a breakdown of the information Tempus AI, Inc. Class A presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Tempus AI, Inc. is a technology company at the forefront of precision medicine, leveraging artificial intelligence to enhance patient care and therapeutic development. In its latest earnings report for Q3 2025, Tempus AI, Inc. showcased significant growth, with revenues reaching $334.2 million, marking an 84.7% increase year-over-year. The company’s Genomics business was a major contributor, with revenues soaring by 117.2% to $252.9 million, while its Data and Services segment grew by 26.1% to $81.3 million. Tempus also achieved a positive Adjusted EBITDA of $1.5 million, a notable improvement from a loss in the previous year. The company continues to expand its capabilities, as evidenced by its acquisition of Paige, an AI company specializing in digital pathology, and its selection by ARPA-H for a significant cancer therapy program. Looking ahead, Tempus AI, Inc. remains optimistic about its growth trajectory, aiming for approximately $1.265 billion in revenue by the end of 2025, driven by ongoing investments in AI and precision medicine solutions.